Database : MEDLINE
Search on : uveitis [Words]
References found : 19939 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 1994 go to page                         

  1 / 19939 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29523105
[Au] Autor:Nakahara H; Kaburaki T; Tanaka R; Matsuda J; Takamoto M; Ohtomo K; Okinaga K; Komae K; Numaga J; Fujino Y; Aihara M
[Ad] Address:Department of Ophthalmology, University of Tokyo Graduate School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
[Ti] Title:Monoclonal immunoglobulin heavy chain gene rearrangement in Fuchs' uveitis.
[So] Source:BMC Ophthalmol;18(1):74, 2018 Mar 09.
[Is] ISSN:1471-2415
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:BACKGROUND: Fuchs' uveitis (FU) is occasionarlly complicated with heavy vitreous opacity. We have performed vitrectomy procedures to remove vitreous opacity in affected patients as part of differential diagnosis for primary vitreoretinal lymphoma (PVRL). CASE PRESENTATION: We retrospectively reviewed the clinical records of five patients who first visited the Uveitis Clinic of the University of Tokyo Hospital between 2009 and 2013, were diagnosed with FU and underwent a vitrectomy for removal of dense vitreous opacity. All were diagnosed as FU by ocular findings and elevation of Goldmann-Witmer coefficient (GWC) value for the rubella virus (RV) antibody. In examinations of the vitreous body, cytological diagnosis, elevation of IL-10/IL-6 ratio, and the kappa/lambda ratio in flow cytometry findings were negative in all cases, whereas monoclonal immunoglobulin heavy chain (IgH) gene rearrangement was positive in 4 cases and negative in 1 case. CONCLUSIONS: Although monoclonal IgH gene rearrangement is thought to be a reliable biomarker for PVRL, a high percentage of vitreous specimens from our FU patients showed pseudo-positive results. Ophthalmologists must take care regarding possible pseudo-positive findings when performing differential diagnosis between FU and PVRL. Combinations of results of cytological diagnosis, IL-10/IL-6 ratio, kappa/lambda ratio, and IgH gene rearrangement may be necessary for a definitive diagnosis of PVRL and differentiation from FU.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:In-Process
[do] DOI:10.1186/s12886-018-0740-3

  2 / 19939 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Clinical Trials Registry
Full text

[PMID]: 29377953
[Au] Autor:Waduthantri S; Zhou L; Chee SP
[Ad] Address:Singapore Eye Research Institute, Singapore, Singapore.
[Ti] Title:Intra-cameral level of ganciclovir gel, 0.15% following topical application for cytomegalovirus anterior segment infection: A pilot study.
[So] Source:PLoS One;13(1):e0191850, 2018.
[Is] ISSN:1932-6203
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:PURPOSE: To investigate the intra-cameral level of ganciclovir following topical application of ganciclovir gel, 0.15% for cytomegalovirus (CMV) anterior segment infection. DESIGN: Non-randomized, prospective, interventional clinical study. METHODS: Patients with active CMV anterior segment infection seen at Singapore National Eye Centre, confirmed by positive CMV real time PCR (RT-PCR) of the aqueous humor, that had not been treated with any form of ganciclovir in the preceding 1 month were recruited. They were treated with ganciclovir gel, 0.15% 1cc 5 times a day. Following 6 weeks of treatment, CMV load in the aqueous humor was measured using CMV RT-PCR and the ganciclovir drug levels in tears and aqueous humor were measured using high-performance liquid chromatography-mass spectrometry. The clinical features of the disease activity and the central corneal thickness (CCT) were recorded at the baseline and post-treatment. RESULTS: There were 29 eyes of 29 patients, of which 23 eyes had CMV anterior uveitis and 6 eyes had CMV endotheliitis. At the end of week 6, 26 eyes had undetectable CMV titre in the aqueous humor and no anterior chamber (AC) activity. Two patients had an increased CMV titre and increased AC inflammation. Both of these patients were non-compliant with the treatment. One patient had a reduced CMV titre in the aqueous humor with minimal AC inflammation. The mean ganciclovir concentration in the aqueous humor and the tears were 17.4 ± 30.6 ng/ml and 20,420.9 ± 33,120.8 ng/ml respectively. Mean CCT was 552.2 ± 42.3 microns. There was a weak correlation between the ganciclovir concentration in the aqueous humor and CCT (Spearmen's r = + 0.42, p = 0.025). There was no significant correlation between the ganiclovir concentration in the tears and CCT (Spearmen's r = + 0.39, p = 0.11). CONCLUSION: Ganciclovir levels in the aqueous humor was below the 50% inhibitory dose (ID50) for CMV replication, following topical application of the ganciclovir gel, 0.15%. TRIAL REGISTRATION: SingHealth Centralized Institutional Review Board, Singapore; R733/17/2010, ClinicalTrials.gov; NCT01647529.
[Mh] MeSH terms primary: Anterior Eye Segment/pathology
Antiviral Agents/administration & dosage
Cytomegalovirus Infections/drug therapy
Ganciclovir/administration & dosage
[Mh] MeSH terms secundary: Administration, Ophthalmic
Adult
Aged
Aged, 80 and over
Chromatography, Liquid
Cytomegalovirus/genetics
Female
Humans
Male
Middle Aged
Pilot Projects
Prospective Studies
Real-Time Polymerase Chain Reaction
Tandem Mass Spectrometry
[Pt] Publication type:CLINICAL STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Name of substance:0 (Antiviral Agents); P9G3CKZ4P5 (Ganciclovir)
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[Js] Journal subset:IM
[Da] Date of entry for processing:180130
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0191850

  3 / 19939 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 27772646
[Au] Autor:Lee CS; Lee AY; Holland GN; Van Gelder RN; Tufail A
[Ad] Address:Seattle, Washington. Electronic address: leecs2@uw.edu.
[Ti] Title:Big Data and Uveitis.
[So] Source:Ophthalmology;123(11):2273-2275, 2016 11.
[Is] ISSN:1549-4713
[Cp] Country of publication:United States
[La] Language:eng
[Mh] MeSH terms primary: Datasets as Topic
Uveitis/complications
[Mh] MeSH terms secundary: Databases, Factual
Delivery of Health Care/standards
Humans
[Pt] Publication type:EDITORIAL; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[Js] Journal subset:IM
[Da] Date of entry for processing:161025
[St] Status:MEDLINE

  4 / 19939 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29521875
[Au] Autor:Weinstein JE; Pepple KL
[Ad] Address:University of Washington, Department of Ophthalmology, Seattle, Washington, USA.
[Ti] Title:Cytokines in uveitis.
[So] Source:Curr Opin Ophthalmol;, 2018 Mar 06.
[Is] ISSN:1531-7021
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:PURPOSE OF REVIEW: Increasing evidence supports Th17 cells as key mediators of ocular inflammatory disease. Cytokines that are important for the development and pathologic function of these cells are potential therapeutic targets in patients with immune mediated uveitis. This review provides an overview of these cytokines including recent insights about their roles in ocular inflammation from laboratory and clinical studies. RECENT FINDINGS: Interleukin (IL)-6, IL-10, IL-17, IL-22, IL-23 and tumour necrosis factor-alpha (TNFα) are cytokines that have been examined for their functional role in uveitis and their relationship to pathologic Th17 cells. Studies in animal models, particularly in experimental autoimmune uveitis (EAU), have been instrumental in studying the role of these cytokines in disease pathogenesis. More recently, studies on aqueous, vitreous and serum from patients with uveitis using flow cytometry and multiplex ELISA bead-based methodologies have provided insights into the contribution of Th17 cells and the related cytokines in ocular inflammatory diseases. The central role of IL-23 in determining the pathologic Th17 fate has made it an effective therapeutic target in systemic diseases such as psoriasis and thereby an attractive potential target for patients with immune-mediated uveitis. SUMMARY: Th17 cells, and their related cytokines, are important inflammatory mediators in autoimmune uveitis. Animal and human studies continue to provide new information to direct development of new cytokine-targeted therapies for patients with uveitis.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:Publisher
[do] DOI:10.1097/ICU.0000000000000466

  5 / 19939 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29519769
[Au] Autor:Paz-Solarte JA; Hernández-Garfella M; Rueda-Cid A; Campos-Fernández C; Calvo-Catala J
[Ad] Address:Servicio de Reumatología, Hospital Clínico Universitario, Valencia, España. Electronic address: juanalbertopazsolarte@gmail.com.
[Ti] Title:Rara asociación entre la enfermedad de Vogt-Koyanagi-Harada y la artritis reumatoide. Reporte de un caso clínico de la consulta multidisciplinar de uveítis. Rare association between Vogt-Koyanagi-Harada disease and rheumatoid arthritis: Report of a clinical case from the unit of multidisciplinary uveitis.
[So] Source:Reumatol Clin;, 2018 Mar 05.
[Is] ISSN:1885-1398
[Cp] Country of publication:Spain
[La] Language:eng; spa
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:Publisher

  6 / 19939 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29518861
[Au] Autor:Ji XJ; Sun K; Hu ZY; Zhang Y; Ma YP; Sun Z; Li KP; Zhu J; Zhang JL; Huang F
[Ti] Title:[Comparison of clinical manifestations according to HLA-B(27) genotype in ankylosing spondylitis patients: real-world evidence from smart management system for spondyloarthritis].
[So] Source:Zhonghua Nei Ke Za Zhi;57(3):179-184, 2018 Mar 01.
[Is] ISSN:0578-1426
[Cp] Country of publication:China
[La] Language:chi
[Ab] Abstract:The aim of this study was to set up a large, longitudinal and prospective database to compare the clinical manifestations in human leucocyte antigen (HLA)-B(27) positive and negative patients with ankylosing spondylitis(AS) based on real-world evidence in Chinese population. A total of 897 outpatients with confirmed AS were recruited consecutively by smart management system for spondyloarthritis (SMSP) from April 13, 2016 to June 6, 2017 in Chinese PLA General Hospital from 30 provinces and autonomous regions. 801 patients with HLA-B(27) data were included in the analysis. Demographic and clinical parameters including Bath ankylosing spondylitis disease activity index (BASDAI), Bath ankylosing spondylitis functional index (BASFI), ankylosing spondylitis disease activity score (ASDAS), arthritis, enthesitis, Bath ankylosing spondylitis metrology index (BASMI), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were compared between HLA-B(27) positive and negative groups. A total of 801 patients were included in the analysis with an average age of (30.7±8.8) years. There were 659 males and 142 females and HLA-B(27) was present in 88.0%(705/801). Males were significantly more in HLA-B(27) positive patients [83.3%(587/705) vs. 75.0%(72/96); 0.047].The average age at disease onset was (22.3±7.6)years in HLA-B(27) positive patients and (24.4±8.7) years in HLA-B(2)7 negative ones ( 0.028).There was significant difference in diagnose delay between two groups [14.3(2.5,43.6)months in HLA-B(27) positive patients vs. 20.3(5.0,67.4) months in HLA-B(27) negative ones, 0.041]. Anterior uveitis was found to be significantly more common in HLA-B(27) positive patients [18.9% (133/705)vs.7.3%(7/96), 0.005], and knee involvement less common in HLA-B(27) positive patients [4.0%(27/682) vs.10.0%(9/90), 0.010], conversely. CRP[6.5(3.0, 16.4)mg/L vs. 3.5(1.6, 12.3)mg/L] and ESR[11.0(4.0, 24.0)mm/1h vs. 7.0(3.0, 16.0)mm/1h] were significantly higher in HLA-B(27) positive patients( 0.005,0.013, respectively).But no differences in BASDAI,ASDAS,BASFI and BASMI were obtained between two groups. HLA-B(27) positive patients had a higher proportion of males, a younger age of onset and a greater risk for occurrence of anterior uveitis, suggesting a poorer prognosis.
[Pt] Publication type:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:In-Process
[do] DOI:10.3760/cma.j.issn.0578-1426.2018.03.006

  7 / 19939 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29518184
[Au] Autor:Ottaviano G; Salvatore S; Salvatoni A; Martelossi S; Ventura A; Naviglio S
[Ad] Address:Pediatric Department, Ospedale "F. Del Ponte", Università dell'Insubria, Varese, Italy.
[Ti] Title:Ocular Manifestations of Pediatric Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
[So] Source:J Crohns Colitis;, 2018 Mar 06.
[Is] ISSN:1876-4479
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Background and aims: Ocular extraintestinal manifestations (O-EIMs) are known complications of Crohn's disease (CD), ulcerative colitis (UC) and inflammatory bowel disease unclassified (IBD-U). However, data on their prevalence in children are scarce and there are no clear recommendations on which follow-up should be offered. We aimed to review available data on O-EIMs in children. Methods: In January 2018, we performed a systematic review of published English literature using PubMed and EMBASE databases using disease-specific queries. Results: Fifteen studies (7467 patients) reported data on O-EIMs prevalence in children. Overall prevalence of O-EIMs was 0.62% - 1.82%. Uveitis was the most common O-EIM. Meta-analysis showed that children with CD are at increased risk of O-EIMs as compared with children with UC and IBD-U (OR 2.70, 95% CI 1.51-4.83). Five studies (357 patients) reported data on ophthalmologic screening in asymptomatic children: mild asymptomatic uveitis was identified in a variable proportion of patients (1.06%-23.1%), more frequently in male patients with CD and colonic involvement. No evidence of ocular complications from untreated uveitis was detected. Twenty-three case reports (24 patients) were identified. Conclusions: Data on O-EIMs in children are scarce. Prevalence of O-EIMs is lower than in adults but may be underestimated because of the possibility of asymptomatic uveitis; however, the long-term significance of this condition is unknown. Children with CD may be at increased risk of O-EIMs. No recommendations on routine ophthalmological examination can be made but a low threshold for ophthalmologic referral should be maintained. Larger studies in pediatric IBD populations are needed.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:Publisher
[do] DOI:10.1093/ecco-jcc/jjy029

  8 / 19939 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29430976
[Au] Autor:Comstock TL; Sheppard JD
[Ad] Address:a Ophthalmic Medical Affairs Consultant , Rochester , NY , USA.
[Ti] Title:Loteprednol etabonate for inflammatory conditions of the anterior segment of the eye: twenty years of clinical experience with a retrometabolically designed corticosteroid.
[So] Source:Expert Opin Pharmacother;19(4):337-353, 2018 Mar.
[Is] ISSN:1744-7666
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:INTRODUCTION: Topical corticosteroids are an important pharmacotherapy for the management of various inflammatory conditions affecting the anterior segment of the eye. However, medications in this class are associated with well-known risks including increased intraocular pressure (IOP) and development of cataracts. The topical corticosteroid loteprednol etabonate (LE) was developed with the specific intention of minimizing these side effects. Areas covered: The focus of this review is to examine published efficacy and safety data for LE, a drug engineered to undergo rapid metabolism to inactive metabolites with the goal of improved safety. Two decades of clinical research focused on LE formulations are reviewed, including the use of LE in combination with tobramycin. The cumulative body of experience affirms the concept that the molecular design of LE confers certain safety benefits without compromising the desired anti-inflammatory efficacy of a topical corticosteroid. Expert opinion: Loteprednol etabonate is a mainstay for topical therapy of a wide variety of commonplace and niche conditions of the ocular surface and the anterior segment, including in the healing post-operative patient. Its versatility and safety allow eye care providers to recommend both acute induction as well as chronic maintenance therapy with appropriate follow-up.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:In-Process
[do] DOI:10.1080/14656566.2018.1439920

  9 / 19939 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29397459
[Au] Autor:Leclercq M; Le Besnerais M; Langlois V; Girszyn N; Benhamou Y; Ngo C; Levesque H; Muraine M; Gueudry J
[Ad] Address:Normandie Université UNI Rouen, Service de Médecine Interne, CHU Charles Nicolle, 76000, Rouen, France. mat3leclercq@gmail.com.
[Ti] Title:Tocilizumab for the treatment of birdshot uveitis that failed interferon alpha and anti-tumor necrosis factor-alpha therapy: two cases report and literature review.
[So] Source:Clin Rheumatol;37(3):849-853, 2018 Mar.
[Is] ISSN:1434-9949
[Cp] Country of publication:Germany
[La] Language:eng
[Ab] Abstract:Biotherapies appear as potential drugs for the treatment of inflammatory noninfectious uveitis. In this report, we show that tocilizumab, an anti-IL-6 agent, greatly improved two patients with birdshot chorioretinopathy refractory to conventional immunosuppressive drugs, interferon α2a, and anti-TNFα agents. After a follow-up of 22 months, patients exhibited an improvement of both visual acuity and macular edema. A corticosteroid-sparing effect was achieved in both cases.
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1802
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:In-Process
[do] DOI:10.1007/s10067-018-4007-4

  10 / 19939 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 29241207
[Au] Autor:Borrego-Sanz L; Abásolo L; López-Abad C; Fernández-Gutiérrez B; García-Feijoo J; Diaz-Valle D; Pato E; Rodriguez-Rodriguez L
[Ad] Address:Ophthalmology Department and Health Research Institute (IdISSC), Hospital Clínico San Carlos, Madrid, Spain.
[Ti] Title:Disease Remission in Children and Adolescents with Intermediate Uveitis: A Survival Analysis.
[So] Source:Ophthalmologica;239(2-3):151-158, 2018.
[Is] ISSN:1423-0267
[Cp] Country of publication:Switzerland
[La] Language:eng
[Ab] Abstract:PURPOSE: To report the incidence rate (IR) of remission in pediatric noninfectious intermediate uveitis (IU). METHODS: Longitudinal retrospective cohort study, including 19 patients (32 eyes) between 1985 and 2014, followed-up until loss or January 2016. Remission was defined following the Standardization of Uveitis Nomenclature workshop criteria, prolonged remission as a remission spanning 12 months and until the end of follow-up, and relapse as recurrence of inflammatory activity in an eye in remission. RESULTS: Median follow-up time was 6.3 years. IRs (95% confidence interval) for remission, relapse, and prolonged remission were 18.6 (13.1-26.5), 32.3 (20.6-50.7), and 6.7 (3.8-11.9) episodes per 100 eye-years, respectively. 48% of eyes relapsed in the first year following remission. 25 and 50% of eyes achieved prolonged remission after 5 and 10 years of follow-up, respectively. CONCLUSIONS: Inflammatory relapses may be frequent in noninfectious IU affecting children and adolescents, appearing early after remission. Also, prolonged remission seems infrequent, being achieved late during follow-up.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1712
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:In-Process
[do] DOI:10.1159/000485262


page 1 of 1994 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information